---
title: How Long Until Revenue? MedTech Timeline Planning
description: How long until a MedTech startup sees its first euro? Realistic revenue timelines by class, hidden delays, and what actually shortens the path.
authors: Tibor Zechmeister, Felix Lenhard
category: MedTech Startup Strategy & PMF
primary_keyword: MedTech revenue timeline
canonical_url: https://zechmeister-solutions.com/en/blog/how-long-until-revenue-medtech-timeline
source: zechmeister-solutions.com
license: All rights reserved. Content may be cited with attribution and a link to the canonical URL.
---

# How Long Until Revenue? MedTech Timeline Planning

*By Tibor Zechmeister (EU MDR Expert, Notified Body Lead Auditor) and Felix Lenhard.*

> **A realistic MedTech revenue timeline is 18 to 48 months from first prototype to first euro, depending on device class, reimbursement pathway, and whether a Notified Body is involved. Most founders underestimate by 6 to 12 months. The surprise is rarely certification itself — it is what happens on either side of it.**

**By Tibor Zechmeister and Felix Lenhard.**

## TL;DR
- A self-certified Class I device can reach first revenue in 9 to 15 months if the intended purpose is tight and the QMS is lean.
- A Class IIa or IIb device with Notified Body involvement typically takes 24 to 36 months from prototype to first euro, and Notified Body queues add 3 to 9 months on top.
- Class III devices rarely reach revenue in under 36 months, and 48 months is common when clinical investigations are required.
- Reimbursement coding and hospital procurement cycles frequently add 6 to 18 months after CE marking — this is where founders get blindsided.
- What shortens the timeline: narrow intended purpose, early Notified Body contact, parallel workstreams. What does not: pushing suppliers, switching Notified Bodies mid-project, or trying to compress clinical evaluation.

## Why this matters

Every MedTech founder we work with has a board deck that says "revenue in 18 months." Most of them are wrong by a factor of two. The damage is not the delay itself — it is that the burn rate was planned around the optimistic number, the hires were made against the optimistic number, and the next funding round was sized against the optimistic number.

A realistic MedTech revenue timeline is not pessimism. It is operating hygiene. You cannot subtract what you have not first understood. This post walks through the honest durations, class by class, and names the places where 6 to 12 months quietly disappear.

## What MDR actually says about the timeline

The MDR does not give you a calendar. It gives you obligations, and the calendar emerges from those obligations. The core reference points are:

- **Article 10** sets out the general obligations of manufacturers — a QMS, technical documentation, risk management, clinical evaluation, post-market surveillance, and a PRRC. All of this must exist before placing the device on the market under Article 5.
- **Article 52** defines the conformity assessment procedures, which differ by class. Class I devices other than sterile, measuring, reusable surgical, or Class Is/Im/Ir can self-certify. Classes IIa, IIb, and III require a Notified Body to assess the QMS and, depending on the annex chosen, the technical documentation.
- **Annex IX** (full QMS plus technical documentation assessment) is the most common route for software and Class II devices. It is also the route with the longest Notified Body engagement.
- **Article 10(9)** requires a QMS that complies with the MDR; in practice this is demonstrated via EN ISO 13485:2016+A11:2021.

The regulation does not tell you how long any of this takes. What determines the duration is: how mature your intended purpose is, how complete your technical documentation is when the Notified Body opens the file, and how congested your chosen Notified Body is at that moment.

## A worked example: Class IIa software device

A founder builds a diagnostic decision-support app that qualifies as a medical device under Rule 11. Class IIa. Notified Body route under Annex IX. Here is the honest schedule:

- **Months 0 to 6** — intended purpose definition, risk management file under EN ISO 14971, initial software architecture and requirements under EN 62304, first draft of the clinical evaluation plan.
- **Months 6 to 12** — QMS implementation under EN ISO 13485:2016+A11:2021, first internal audit, management review, usability engineering file under EN 62366-1. The team hires or contracts a PRRC.
- **Month 12** — application sent to the Notified Body. The NB acknowledges receipt and puts the file in the queue.
- **Months 12 to 18** — waiting. The NB is not reading your file yet. This is the bottleneck nobody warned you about.
- **Months 18 to 24** — Stage 1 audit (documentation review), Stage 2 audit (QMS on-site), technical documentation review, clarification rounds. Expect at least one round of major findings.
- **Months 24 to 28** — findings closed, CE certificate issued, EU Declaration of Conformity signed, device registered.
- **Months 28 to 34** — first sales cycle. In many EU markets this means hospital procurement lists, tender windows, and pilot deployments before a purchase order.
- **Month 34 onwards** — first invoice. First euro in the bank maybe 60 days after that.

That is 36 months from founding to first recognised revenue, for a device that the founder initially scoped as "12 months to CE." The delta is not regulatory overreach. The delta is reality.

## Where the 6 to 12 month surprises hide

After guiding many companies through this path, the same four surprises keep showing up.

**The Notified Body queue is not a queue you can pay to skip.** Once you submit, you wait. The queue is measured in months, not weeks, and no Notified Body we know of sells a premium lane. Engaging your NB early — ideally during pre-application dialogue — is the only thing that moves your position in line.

**Clinical evaluation is not a literature review.** It is a systematic appraisal under Article 61 and Annex XIV. If your equivalence claim is weak or your state-of-the-art section is thin, the NB will come back for a second round. Each round costs 6 to 12 weeks. Budget for at least one round of revisions — two for novel devices.

**Reimbursement is a separate game.** CE marking gives you the right to sell. It does not give you a reimbursement code. In Germany, the DiGA fast-track pathway for digital health applications runs in parallel to CE but still takes months. In France, LPPR listing can take a year or more. In most markets, the hospital CFO is a gate you cannot unlock with a CE certificate alone.

**The first sales cycle is long.** Hospitals do not buy on Tuesday because you certified on Monday. Procurement committees meet monthly or quarterly. Pilot sites want to see real-world evidence before they commit. Your first euro typically arrives 4 to 9 months after your first commercial conversation.

## The Subtract to Ship playbook

The timeline is a function of decisions you make early. You cannot undo those decisions by working harder later. Here is what actually shortens the path without cutting corners.

**Narrow the intended purpose, ruthlessly.** A tighter intended purpose means a smaller clinical evaluation, fewer GSPR to demonstrate, and a smaller technical file. A diagnostic app for "any dermatological condition" is a 36-month project. The same app for "adult melanoma screening only" might be a 22-month project. Every claim you add is paid for in months. This is the core of Subtract to Ship: what you remove is how you ship.

**Engage your Notified Body before you need them.** Book a pre-application meeting 6 months before you plan to submit. Ask what they want to see. Ask how long their current queue is. Ask who your reviewer will be. A good Notified Body will tell you. A bad one will not answer — and that is information too. See our guide on choosing the right Notified Body.

**Run workstreams in parallel, not in series.** The founders who ship fastest do clinical evaluation, QMS build-out, software development, and PMS planning as parallel streams from month one. The founders who take longest build the device first, then discover they need a QMS.

**Plan reimbursement from day one, not after CE.** Talk to payers before your design is frozen. If the reimbursement pathway requires a specific data format or outcome measure, you want to know that before you build the product.

**Budget your runway against the 75th percentile, not the median.** If your honest median case is 30 months, raise for 42. A MedTech startup that runs out of money three months before CE is the saddest failure mode we see, and we see it often.

**Do not switch Notified Bodies mid-project.** It adds 6 to 12 months and resets clarification rounds. Pick carefully the first time.

## Reality Check

Work through these questions honestly. If you cannot answer "yes" to most of them, your timeline is optimistic.

1. Have you written down your intended purpose in a single paragraph, and has a regulatory professional reviewed it for scope?
2. Do you know the Notified Body queue length for your chosen NB, as of this quarter?
3. Is your clinical evaluation strategy complete, with equivalence evidence assessed, or are you planning to "figure it out later"?
4. Does your financial model include 6 to 18 months of post-CE reimbursement and procurement delay before first revenue?
5. Have you run at least one full internal audit before sending anything to the Notified Body?
6. Is your PRRC identified and contractually engaged, per Article 15?
7. Have you stress-tested your timeline by adding 40% to every milestone and checking whether the company still survives?

## Frequently Asked Questions

**What is the fastest realistic MedTech revenue timeline?**
For a well-scoped Class I device with self-certification, 9 to 12 months is achievable if the founder has regulatory experience. For Class IIa with Notified Body involvement, 18 months is the theoretical floor and rare in practice.

**Why do Notified Body queues exist?**
There are fewer designated Notified Bodies under MDR than there were under the MDD, and each one has finite reviewer capacity. Demand has exceeded supply since 2021.

**Can I start selling before the CE certificate arrives?**
No. Article 5 prohibits placing a device on the EU market without the applicable conformity assessment completed. You can take orders and run pilots under clinical investigation frameworks, but you cannot invoice as a commercial sale.

**Does reimbursement really take that long?**
In most EU markets, yes. Private self-pay revenue can come faster, but it rarely reaches the volume that makes a MedTech startup sustainable.

**Should I pay a consultant to speed things up?**
A good consultant saves months by preventing dead ends. A bad one adds months by creating paperwork for its own sake. The value is not speed per se — it is avoiding the 6 to 12 month mistakes that cost the most.

**What if I run out of money mid-certification?**
Talk to your Notified Body early, freeze scope, and focus every remaining euro on closing the current assessment. Switching paths mid-stream is almost always worse than finishing the path you started.

## Related reading
- [No-bullshit MedTech startup timelines](/blog/no-bullshit-medtech-startup-timelines) — the honest numbers for every milestone.
- [How long does CE marking take?](/blog/how-long-does-ce-mark-take-honest-timelines) — a deep dive into the certification phase specifically.
- [True cost of CE marking: transparent breakdown](/blog/true-cost-ce-marking-transparent-breakdown) — what the timeline costs in euros.
- [The Notified Body bottleneck](/blog/notified-body-bottleneck) — why queues exist and how to navigate them.
- [MedTech go-to-market strategy](/blog/medtech-go-to-market-strategy) — how to plan the post-CE sales ramp realistically.

## Sources
1. Regulation (EU) 2017/745 on medical devices, consolidated text. Article 5 (placing on the market), Article 10 (manufacturer obligations), Article 15 (PRRC), Article 52 (conformity assessment procedures), Annex IX.
2. EN ISO 13485:2016+A11:2021 — Medical devices QMS requirements.
3. EN ISO 14971:2019+A11:2021 — Application of risk management to medical devices.

---

*This post is part of the [MedTech Startup Strategy & PMF](https://zechmeister-solutions.com/en/blog/category/startup-strategy) cluster in the [Subtract to Ship: MDR Blog](https://zechmeister-solutions.com/en/blog). For EU MDR certification consulting, see [zechmeister-solutions.com](https://zechmeister-solutions.com).*